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A dose-escalation study of cisplatin (CDDP) combined with S-1, a new oral dihydropyrimidine dehydrogenase inhibitory
fluoropyrimidine, was performed to determine the maximum-tolerated dose (MTD), recommended dose (RD), dose-limiting
toxicities (DLTs), and objective response rate (RR) in advanced gastric cancer (AGC). S-1 was given orally at 40mgm
 2 b.i.d. for 21
consecutive days following a 2-week rest. CDDP was planned to be given intravenously on day 8, at a dose of 60, 70, or 80mgm
 2
depending on the DLT. Treatment was repeated every 5 weeks, unless disease progression was observed. In the phase I portion, the
MTD of CDDP was presumed to be 70mgm
 2, because 33.3% of patients (2/6) developed DLTs, mainly neutropenia. Therefore,
the RD of CDDP was estimated as 60mgm
 2. In the phase II portion, 19 patients including six patients of the RD phase I portion
were evaluated. The median administered courses was four (range: 1–8). The incidences of severe (grades 3–4) haematological and
nonhaematological toxicities were 15.8 and 26.3%, respectively, but all were manageable. The RR was 74% (14/19, 95% confidence
interval: 54.9 90.6%), and the median survival day was 383. This regimen is considered to be active against AGC with acceptable
toxicity.
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The significant survival benefit of 5-fluorouracil (5-FU)-based
chemotherapy for unresectable advanced gastric cancer (AGC)
compared with best supportive care is reported (Murad et al, 1993;
Glimelius et al, 1994; Pyrhonen et al, 1995). To improve the
objective response rate (RR) and survival for AGC, many
combination regimens based on 5-FU and its derivatives
have been studied clinically. However, the median survival
times (MST) with these combination chemotherapies were
only 5.7–10.5 months (Wils et al, 1991; Kelsen et al, 1992;
Kim et al, 1993; Vanhoefer et al, 2000). Although some
combination chemotherapies showing superior results in AGC
have been reported (Wils et al, 1991; Webb et al, 1997), there
is no regimen accepted worldwide as the standard treatment
(Ohtsu et al, 2003). Therefore, we need to develop new agents and
combination chemotherapy regimens to achieve greater survival
benefit in AGC.
As administered 5-FU is rapidly degraded by dihydropyrimidine
dehydrogenase (DPD), DPD seems to be a typical prognosis factor
against 5-FU-based chemotherapy (Takabayashi et al, 2000).
Therefore, a new oral drug that inhibits DPD namely, DPD
inhibitory fluoropyrimidine (DIF), was invented (Diasio, 1999). S-
1 is a new oral DIF, and consists of tegafur (FT), 5-chloro-2,4-
dihydroxypyridine (CDHP), and potassium oxonate (Oxo) at a
molar ratio of 1:0.4:1. It achieved high efficacy without increasing
gastrointestinal (GI) toxicity, based on biochemical modulation
theory (Shirasaka et al, 1996).
In two late phase II clinical studies for AGC in Japan,
the combined RR of the two studies was 44.6%, with a very low
(2.0%) incidence of grade 3 diarrhoea (Sakata et al, 1998; Koizumi
et al, 2000). S-1 was approved in Japan for AGC under an
accelerated approval regulation system in 1999, and for head and
neck cancer in 2001, and clinical trials against colorectal (Ohtsu
et al, 2000), breast (Sano et al, 2000), and lung cancer (Kawahara
et al, 2001) are now ongoing and high responses have been
reported. The phase II studies of S-1 against gastric (Chollet et al,
2003) and colorectal cancer (den Brande et al, 2003) in Europe by
EORTC-Early Clinical Study Group also revealed high efficacy.
Therefore, S-1 can be anticipated to be one of the key drugs
for AGC.
Several combination regimens show high RR; however,
toxic effects limited the survival benefit (Kelsen et al, 1992;
Kim et al, 1993; Vanhoefer et al, 2000; Ohtsu et al, 2003).
Therefore, new chemotherapy regimens to achieve survival benefit
with low toxicities are needed. Combinations of 5-FU and cisplatin
(CDDP) were synergistic in preclinical (Scanlon et al, 1986;
Yamada et al, 1990; Shirasaka et al, 1993) and clinical studies
(Rougier et al, 1994) on AGC with acceptable toxicity. Based on
these studies, we conducted a phase I/II study of S-1 in
combination with CDDP.
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Patients
Prior to entry, tumour size was determined by chest or GI X-ray,
endoscopic examination of the upper GI tract, computed tomo-
graphic (CT) scan of the abdomen, barium enema, and bone
scintigram. A complete blood cell count, liver and renal function
test, and urinalysis were executed within 7 days before entry.
The eligibility criteria were as follows: aged 20–74 years;
histologically proven unresectable locally advanced or metastatic
gastric adenocarcinoma; no prior chemotherapy except adjuvant
chemotherapy more than 30 days prior to entry; adequate organ
function, defined as haemoglobin 48.0gdl
 1, leucocyte count
44000–12000mm
 3, platelet count 4100000mm
 3, serum
bilirubin level o1.5mgdl
 1, serum transaminase (aspartate
aminotransferase and alanine aminotransferase) o100Ul
 1, alka-
line phosphatase (ALP) o twice the upper limit of the normal
range (ULN) of each hospital, serum creatinine level less than the
ULN of each hospital, creatinine clearance 450mlmin
 1; Eastern
Cooperative Oncology performance status (PS) 0–2; expected
survival period more than 3 months; and written informed consent
from the patients. Patients with symptomatic brain metastases
were not eligible.
This study was approved by the ethics committees in each
institution.
Treatment and dose escalation schedule
S-1 was given orally at a dose that did not exceed 40mgm
 2 based
on the patient’s body surface area (BSA): BSAo1.25m
2, 40mg;
1.25 1.5m
2, 50mg, and BSA41.5m
2, 60mg, for 21 consecutive
days (b.i.d.) and CDDP was diluted in 400ml physiological saline,
and administered as a 120-min i.v. infusion on day 8. The starting
dose of CDDP was 60mgm
 2 (level 1), which was planned to be
increased in 10mgm
 2 increments to 80mgm
 2 unless max-
imum-tolerated dose (MTD) was achieved. The starting dose of
CDDP corresponded to 66.7 85.7% of the recommended dose
(RD) for gastric cancer in Japan. No intrapatient dose escalation
was allowed. At least three patients were treated at each dose level.
If one of three patients at a given dose developed any dose-limiting
toxicity (DLT), other three or more patients were to be entered at
the same dose. Before proceeding to the next dose level, all
previously treated patients had received at least one course.
This treatment course was repeated every 5 weeks with an
allowance for a delay in treatment if toxicity was observed.
To avoid CDDP-induced renal damage, patients were hydrated
on day 8 with 1500ml 5% glucose, and furosemide was given
30min prior to the start of CDDP infusion, and 4000ml 5% glucose
was continued for another 48h.
The next course was started only for the patient whose organ
biological parameter had been maintained as eligibility criteria,
except the leucocyte count (43000mm
 3) and no disease
progression observed. Prophylactic administration of antiemetic
medication (5-HT3 antagonist plus corticosteroid) at standard
doses was routinely used when CDDP was administered to prevent
nausea and vomiting. The treatment was repeated unless disease
progression or severe toxicity was observed. S-1 was provided by
Taiho Pharmaceutical Co., Ltd (Tokyo, Japan).
Evaluation
A complete blood cell count, liver and renal function test, and
urinalysis were assessed at least once a week during the first
course, and every other week afterwards. Before each course,
additional examinations were performed to evaluate sites.
The National Cancer Institute common toxicity criteria version
2.0 was applied to evaluate the toxicity of this therapy. DLTs were
defined as grade 4 neutropenia lasting more than 3 days, any
febrile grade 3 or 4 (severe) haematological toxicity, or grade 3
nonhaematological toxicity (except nausea and vomiting). It was
also categorised as DLT when the second course treatment was not
resumed within 18 days after the first course. The MTD was
defined as the dose at which 33% or more patients experienced
DLTs during the first course.
Tumour responses were evaluated according to the classification
of the Japanese Research Society for Gastric Cancer based on its
volume, which was estimated by X-ray imaging or CT scan (Nishi
et al, 1995). A complete response (CR) was defined as the
disappearance of all evidence of cancer for at least 4 weeks, and a
partial response (PR) was defined as less than complete, but more
than 50% reduction of tumour volume for at least 4 weeks without
any evidence of new lesions or progression, respectively. No
change was defined as less than a 50% reduction or less than a 25%
increase without any new lesions. Progressive disease (PD) was
defined as a more than 25% increase in a solitary lesion or the
appearance of new lesions. Tumour responses of the primary site
were evaluated by the roentgenographic and endoscopic evaluation
criteria proposed by the Japanese Research Society for Gastric
Cancer. The survival period was calculated from the start of
treatment to death or the latest followed-up day. The time to
remission was defined as the period from the start of treatment to
the onset of PR. The duration of PR was defined as the period from
the onset of PR to the first day when progression was noted. The
eligibility and suitability for assessment and the objective response
to the treatment were reviewed extramurally.
Pharmacokinetics
In the phase I portion, a pharmacokinetic (PK) study was
conducted for FT, 5-FU, CDHP, and Oxo on days 6 and 8 during
the first course to evaluate if any metabolic interactions between
the component of S-1 and CDDP were seen in this study. Whole
blood samples were taken before and 1, 2, 4, and 8h after S-1
administration on days 6 and 8 during the first course.
Statistics
The PK parameters were compared between patients treated with
S-1 alone on day 6, and combined with CDDP on day 8 by paired t-
test.
RESULTS
Between April 1999 and July 2000, 25 patients were entered from
three participating centres. The first 12 patients were entered into
the phase I portion and the next 13 patients were entered into the
phase II portion to confirm the toxicities and efficacy at the RD. All
patients were eligible for toxicity evaluation in any course and
objective response evaluations (Table 1). Six patients had under-
gone gastrectomy and one had also received adjuvant chemother-
apy after gastrectomy. Although all patients had metastatic lesion,
one patient whose lymph node metastasis lesion was too small to
evaluate was evaluated only for primary gastric lesion. Histological
evaluation revealed eight patients to be intestinal type and 17
patients to be diffuse type. A total of 109 courses were given: 14
patients (74%) received four or more courses, and seven patients
(37%) received six to eight courses at level 1 (CDDP: 60mgm
 2),
three patients (50%) received four or more courses, and one
patient (17%) received six courses at level 2 (CDDP: 70mgm
 2).
The median number of courses and duration of therapy per patient
was four (range: 1–8). The median number of course per patient
was four (range: 1–8) at level 1, and four (range: 1–6) at level 2,
respectively. The median duration of therapy per patient was 140
days (range: 21–280) at level 1, and 100 days (range: 18–187) at
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after this combination therapy whose number of course by S-1
alone was four (range: 1–5). Two patients received reduced CDDP
during the second course at each level. One patient received both
reduced S-1 and CDDP doses at level 2.
The median number of days until the start of the second course
after completion of scheduled S-1 in the first course was 14 (range:
7 21 days) among 18 patients who were treated with two courses
or more. Seven out of the 18 patients required more than 14 days
interval to start the second course.
Determination of MTD
In the phase I portion at level 1, one patient developed grade 3
neutropenia during the first course and required 20 days to start
the second course, but the other two patients in the same cohort
showed no DLT. An additional three patients were enrolled for
safety evaluation, but overall only one of the total of six patients
developed a DLT at 60mgm
 2 of CDDP. As dose level 2, two of six
patients exhibited DLTs in the first course, one of whom had grade
4 neutropenia, and the other had grade 4 anorexia concomitant
with grade 3 leucopenia, colitis, and febrile neutropenia. The
frequency of severe haematological toxicities increased according
to the increment of the CDDP dose (Table 2a). Based on these
results, dose level 2 was declared as the MTD, and level 1 was
declared as the RD in the following phase II portion. Thus no case
was treated with the originally scheduled 80mgm
 2 CDDP. The
phase II portion was continued with treatment of 60mgm
 2 CDDP
on day 8, and 40mgm
 2 S-1 from days 1 to 21 every 5 weeks,
followed by a 2-week rest.
Safety
In the phase II portion, the most frequently observed severe
(grades 3 and 4) haematological toxicity was neutropenia (three
cases, 16%). Frequently observed nonhaematological toxicities (all
events) included anorexia (18 cases, 95%), nausea (13 cases, 68%),
and vomiting (seven cases, 37%) even though prophylactic
antiemetic medications were given after CDDP infusions. In
addition, the overall incidence of diarrhoea was 32% (six out of
19); however, grade 3 diarrhoea was observed only in one out of 19
(5.3%), and recovered within 2 days (Table 2b).
The median number of days at which grade 3 neutropenia
occurred was 29 days (range: 26–69 days) at level 1, whereas the
median neutrophil nadir was on day 25 (range: 21–28 days) at
level 2, with no differences between dose levels.
During this study, two patients received granulocyte colony-
stimulating factor because of neutropenia. Incidences of the worst
grade toxicities in patients treated with the RD were grade 1 (one
case, 5.3%), grade 2 (nine cases, 47.4%), grade 3 (six cases, 31.6%),
and grade 4 (two cases, 10.5%), respectively. Neither treatment-
related death nor delayed severe toxicity was observed.
Efficacy
A total of 19 patients were evaluated to determine the RR at the
RD. Of these, six patients were treated with the RD of 60mgm
 2
CDDP in the phase I portion and 13 patients were treated with the
same CDDP dose in the phase II portion. The RR at the RD in the
phase II portion was 73.7% (14/19, 95% confidence interval (CI):
48.8 90.9%). The RR of all 25 eligible patients was 76% (19/25,
95% CI: 54.9 90.6%); four patients showed stable disease as their
best response, two patients had PD. The median time to
progression was 179 days (range: 24–384) in the phase II portion
(Table 3). The median time to PR and the median overall durations
of response in 19 responders were 29 (range: 24 64) and 162 days
(range: 63 244), respectively. Two responders treated at level 1
were able to adapt gastrectomy after four courses of this
combination therapy.
Subgroup analysis by tumour lesion and pathological type for
the 25 patients showed that the RR was 67% (4/6) for liver
metastasis, 76% (16/21) for lymph node metastasis, and 74% (14/
19) for primary lesions, and the RR according to pathological type
was 75% (6/8) for the intestinal type, and 76% (13/17) for the
diffuse type.
The MST of all eligible patients was 383 days (95% CI: 256 569)
and 1- and 2-year survival rates were 52 and 20%, respectively. The
median follow-up time for survival analysis was 789 days.
Table 1 Patient characteristics
Phase I portion Phase II portion
CDDP (mgm
 2)6 07 0 6 0
No. of patients 6 6 19
Age (years)
Median 60.5 63.5 60
Range 39–71 31–72 39–72
o65 4 5 13
X65 2 1 6
Sex
Female 1 2 2
Male 5 4 17
Performance status
04 5 1 4
12 1 4
20 0 1
Pathology
Intestinal 2 2 6
Diffuse 4 4 13
Gastrectomy 0 1 5
Adjuvant chemotherapy 0 0 1
CDDP¼cisplatin.
Table 2 Toxicity incidence
(a)
Phase I portion
(b)
Phase II portion
Course
First course All courses
CDDP (mgm
 2)6 0 7 0 6 0
No. of patients 6 6 19
Toxicity/grade
All
events
Grade
3/4
All
events
Grade
3/4
All
events
Grade
3/4
Haematological
Leucopenia 2 0 6 2 15 1
Neutropenia 4 1 6 3 13 3
Anaemia 2 0 4 2 10 3
Thrombocytopenia 1 0 3 1 10 0
Nonhaematological
Anorexia 5 0 6 1 18 5
Nausea 2 0 3 0 13 3
Vomiting 0 0 2 0 7 2
Diarrhoea 0 0 1 0 6 1
Grade is based on the National Cancer Institute common toxicity criteria, version 2.0.
CDDP¼cisplatin.
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Plasma PK analysis was performed on samples obtained from 12
patients during the first course of the phase I portion for S-1
components and total platinum (Table 4). There were no
significant differences between the two PK parameters of S-1
components on days 6 and 8.
DISCUSSION
Two phase II studies of S-1 for AGC patients who had not
previously received chemotherapy as a single agent were
conducted in Japan (Sakata et al, 1998; Koizumi et al, 2000).
Examining those pooled results, the RR rate was 44.6% (45/101,
95% CI: 35.2 54.3), MST was 244 days (95% CI: 172 319), and 1-
and 2-year survival rates were 36.6 and 16.5%, respectively.
Subgroup analysis of the objective RR in the two S-1 phase II
studies revealed that the well-differentiated cell type (intestinal
type) was less sensitive to S-1 (RR¼35%, 16/46) than the poorly
differentiated type (diffuse type, RR¼53%, 29/55). The results of
phase II studies suggested that S-1 is one of the most active
antitumour single agents for AGC patients and is even comparable
to recent combination therapies. Based on these data, to achieve
more survival benefit, we therefore planned combination therapy
of S-1 with another antitumour agent with a different mechanism
of action, because this might obtain better efficacy including
longer survival, as a clinical benefit.
We selected CDDP as the combination agent to be used with S-1,
because CDDP has been widely used in combination therapy for
AGC patients (Rougier et al, 1994), and synergistic activity with 5-
FU and its derivatives has been reported in animal models
(Scanlon et al, 1986; Yamada et al, 1990; Shirasaka et al, 1993).
As most toxicities of S-1 in phase II studies appeared at 4 weeks
of consecutive S-1 administration, a new combination therapy of
S-1 with CDDP was planned in which S-1 was to be administered
daily for 3 consecutive weeks, that is, 1 week less than the period at
which toxicities such as leucopenia appeared. In addition, CDDP
showed the best activity when given 8 days after the start of daily
UFT administration (Ichinose et al, 1995). Therefore, CDDP was
administered on day 8 of 21-day consecutive S-1 administration. In
this combination phase I/II study, S-1 was administrated at the RD
(80mgm
 2 in a day) and the CDDP dose was escalated from
60mgm
 2 as level 1 to 70mgm
 2 at level 2. According to the
results of the phase I portion, the RD of CDDP combined with S-1
was designated as 60mgm
 2 with a DLT of myelosuppression, and
in the phase II trial S-1 was orally administered daily for 21
consecutive days followed by a 2-week rest, and CDDP (level 1)
was intravenously administered on day 8 of every 5-week period.
The severity of neutropenia increased with the dose of CDDP in
this study, and grade 4 neutropenia was seen in one of six patients
(16.7%) when 70mgm
 2 of CDDP was administered with S-1.
Furthermore, thrombocytopenia became slightly more marked,
although it had been infrequent in S-1 single therapy. These results
may lead to the conclusion that CDDP dose-dependently increases
the myelosuppressive toxicity of S-1.
For the nonhaematological toxicity, GI toxicity, that is,
diarrhoea was observed in this combination therapy. The
incidence of diarrhoea was 9.9% (total) and 2.0% (grades 3 and
4) by S-1 single therapy (Sakata et al, 1998; Koizumi et al, 2000). It
suggests that in combination with CDDP, the total incidence of
diarrhoea was increased a little; however, severe diarhoea was
nearly the same and uncommon, and in any study diarrhoea was
manageable, similar to those reported for UFT (Ichinose et al,
1995; Borner et al, 2002).
The PK results of drugs were similar to the previous results
obtained from single-agent therapy (Hirata et al, 1999). As there
was no PK difference for any S-1 component on day 6, before
CDDP administration, and on day 8 after CDDP administration, no
PK interaction of CDDP in S-1 metabolism was suggested.
In this study, the overall RR of all eligible patients was 76%. The
RR in this combination therapy was high, not only in the diffuse
type subgroup, 76%, but also in the intestinal-type subgroup, 75%.
The MST (383 days) of our study was longer than in the S-1 single-
agent phase II study, or other combination chemotherapy phase II
results for AGC patients (Sakata et al, 1998; Koizumi et al, 2000;
Kulke, 2000). Based on these data, combination chemotherapy
using S-1 and CDDP was suggested to be worthwhile.
It is reported that the vascular endothelial growth factor (VEGF)
is more frequently expressed in well-differentiated tumours, and
that it promotes angiogenesis in human gastric carcinoma
(Tanigawa et al, 1997) and also that the prognosis in the group
with high VEGF-C expression was significantly poorer than that in
the group with lower VEGF-C expression (Takahashi et al, 2002).
The combination of CDDP with S-1 therapy is reported to show
higher response than S-1 alone, in VEGF-positive gastric cancer
patients, which may also support the high objective RR and long
survival in this phase I/II combination study (Hironaka et al,
2002). Due to its potent angiogenic activity, VEGF is supposed to
contribute to metastasis including peritoneal metastasis, a
representative life-threatening condition in gastric cancer. S-1
showed superior therapeutic efficacy against peritoneal metastasis
in nude mice (Mori et al, 2003) and clinically, alone (Iwazawa et al,
2002) or in combination with CDDP (Nakamura et al, 2002). The
results suggest good therapeutic effect of S-1 in terms of survival
Table 3 Objective response rate and time to progression
N CR PR NC PD Response (%) 95% CI TTP (day) Range
Phase II portion 19 0 14 3 2 73.7 48.8–90.9% 179 24–384
Total 25 0 19 4 2 76.0 54.9–90.6% 162 24–384
CR¼complete response; PR¼partial response; NC¼no change; PD¼progressive disease; CI¼confidence interval; TTP¼time to progression (median).
Table 4 Pharmacokinetic parameters of S-1 component after oral
administration of S-1 alone, or with CDDP
CDDP: 60mgm
 2 CDDP:70mgm
 2
AUC(0–8)
(nghml
 1)
Cmax
(ngml
 1)
AUC(0–8)
(nghml
 1)
Cmax
(ngml
 1)
Day 6 (S-1 alone)
FT 22724710693 351771392 23860712059 337871574
5-FU 670.97155.8 136.8740.3 860.67466.4 166.3778.2
CDHP 1193.67258.1 308.9795.1 1031.97125.2 219.7717.2
Oxo 373.07196.1 89.9762.4 291.17112.9 61.3726.2
Day 8 (with CDDP)
FT 2093078631 323671119 21192711401 310471572
5-FU 573.87148.7 111.9733.6 782.07326.6 144.9742.6
CDHP 1054.97144.8 241.6762.6 1127.07191.4 258.2766.5
Oxo 282.8799.1 63.2725.7 335.17177.2 68.1735.4
Values are mean+s.d. (n¼6). CDDP¼cisplatin; FT¼tegafur; 5-FU¼5-fluorouracil;
CDHP¼5-chloro-2, 4-dihydroxypyridine; oxo¼potassium oxonate.
S-1 combined with CDDP in advanced gastric cancer
W Koizumi et al
2210
British Journal of Cancer (2003) 89(12), 2207–2212 & 2003 Cancer Research UK
C
l
i
n
i
c
a
lbenefit and increased QOL, as a result of improving several
symptoms related to peritoneal metastasis.
The effect of S-1 in combination with CDDP in the present study
was shown to be as good as in previous studies based on 5-FU
(Kulke, 2000), with no increasing toxicity. Even though the present
study is only a limited experience, a further phase III study to
confirm the efficacy of combination therapy of S-1 with CDDP is
warranted.
Oral chemotherapy has the advantage of greater patient
convenience and acceptance with potential cost saving. It is
reported that if equivalent response is achieved, patients prefer
oral to intravenous medication (Liu et al, 1997). For fluoropyr-
imidine, most patients selected oral UFT, which is a kind of DIF
rather than intravenous 5-FU (Borner et al, 2002), and UFT has
been proposed to raplace i.v. 5-FU as a first-line therapy for
metastatic colorectal cancer (Stabuc, 2003). The same appears to
be true for not only oral S-1 alone but also in combination with
CDDP therapy, which needs limited hospitalisation.
In Japan, several phase II studies using 5-FU combined with
CDDP have been tested for AGC, employing various dosage and
treatment schedules. However, based on the results of the
JCOG9205 phase III study, 5-FU single therapy is still recognised
as the standard first-line chemotherapy (Ohtsu et al, 2003).
In addition, currently, a randomised phase III study (5-FU
vs S-1 vs CPT-11 with CDDP) for AGC patients as the
first-line chemotherapy is underway in Japan (JCOG9912). We
also initiated a randomised phase III study comparing S-1 alone,
and with CDDP for AGC. From these two phase III studies, we may
be able to evaluate the clinical benefit of the regimen using S-1 in
terms of survival benefits and improving the QOL for AGC
patients.
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